B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

Leukemia

Volumn 16, Issue 5, 2002, Pages 911-919

  Kay, N E ^a   Bone, N D ^a   Tschumper, R C ^a   Howell, K H ^a   Geyer, S M ^a   Dewald, G W ^a   Hanson, C A ^a   Jelinek, D F ^a  

^a MAYO CLINIC   (United States)

Author keywords

B CLL; TSP 1; Vascular factors; VEGF

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN; BASIC FIBROBLAST GROWTH FACTOR; CELL RECEPTOR; ENDOGLIN; ENDOSTATIN; MESSENGER RNA; THROMBIN RECEPTOR; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; AUTOCRINE EFFECT; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; ISOLATION AND PURIFICATION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY;

EID: 0036099930     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402467     Document Type: Article

References (65)

1. Tumor angiogenesis: Therapeutic implications
2. Clinical applications of research on angiogenesis
3. Patterns and emerging mechanisms of the angiogenic switch
4. Tumor angiogenesis: Past, present and the near future
5. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
6. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
7. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas
8. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
9. Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid
10. Angiogenesis in multiple myeloma: Correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features
11. Elevated vascular endothelial growth factor (VEGF) serum levels in idopathic myelofibrosis
12. Basic fibroblast growth factor and hematopoiesis
13. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia
14. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
15. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cells chronic lymphocytic leukemia
16. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
17. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias
18. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia
19. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
20. Analysis of clonal B cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic Lymphocytic Leukemia
21. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
22. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors
23. Growth regulatory pathways in myeloma: Evidence for autocrine oncostatin M expression
24. Interleukin-4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8 T cells from B-CLL patients: Impact on clonal B-cell apoptosis
25. Vascular endothelial growth factor induced by hypoxia, a mediator hypoxia-initiated angiogenesis
26. Vascular endothelial growth factor (VEGF) and its receptors
27. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor
28. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1
29. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts
30. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
31. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
32. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells - Possible roles of SP-1
33. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells
34. Interleukin-6 induces the expression of vascular endothelial growth factor
35. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells
36. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
37. Vascular endothelial growth factor: Molecular and biological aspects
38. The biology of vascular endothelial growth factor
39. Endothelial cell survival and apoptosis in the tumor vasculature
40. Vascular endothelial growth factor induces expression of the antiapoptotic protein Bcl-2 and A1 in vascular endothelial cells
41. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor (VEGF)
42. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
43. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells
44. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
45. Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: FLT-1 and VEGF expression in renal mesangial cells
46. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
47. Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells
48. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors
49. VEGF-121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells
50. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
51. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
52. Autocrine stimulation of VEGFR-2 activates human leukemic growth and migration
53. Analysis of TIE receptor tyrosinase in haematopoietic progenitor and leukemia cells
54. Clinical relevance of Flt1 and Tie 1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)
55. Role of protein kinase C zeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression
56. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: Frequent occurrence of dicentric rearrangements and possible association with adverse outcome
57. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
58. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
59. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion
60. Angiogenesis assessed by platelet endothelial cell adhesion molecule antibodies, as indicators of node metastases and survival in breast cancer
61. Endoglin expression on human microvascular endothelial cells - Association with betaglycan and formation of higher order complexes with TGF-beta signaling receptors
62. Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals
63. Thrombospondin-1 is the key activator of TGF-beta 1 in human mesangial cells exposed to high glucose
64. Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone